Antimicrobial resistance (AMR) is a serious global threat. To combat potential epidemic, requires both industry and government collaboration on an international level in antibiotic R&D investment, preventive measures and emergency response. As new resistance mechanisms rapidly spread throughout the developed and developing nations, our existing antibiotic pipeline is under greater risk of failing to resolve many standard medical treatments, and achievements in modern standard medicine and surgery are being compromised.
Expanding horizons on the growing global threat of AMR for almost two decades, Superbugs & Superdrugs will once again play host to an international audience of anti-infective industry experts, providing a focal point to discuss the latest clinical advancements and funding opportunities.
Featured Line-up Includes:
Reasons to Attend:
鈥� Learn new funding opportunities from BARDA to combat antimicrobial resistance
鈥� Understand EU Commission approaches in R&D to support business growth
鈥� Reinvigorate business models with Project DRIVE-AB and to strengthen drug development
鈥� Receive new insights on microbiome profiling
Visit the website for details and earlybird rates.
Expanding horizons on the growing global threat of AMR for almost two decades, Superbugs & Superdrugs will once again play host to an international audience of anti-infective industry experts, providing a focal point to discuss the latest clinical advancements and funding opportunities.
Featured Line-up Includes:
- Richard Bax, Senior Partner, Transcrip Partners
- Lloyd Czaplewski, Director, Chemical Biology Ventures
- Line Matthiessen, MD PhD, Head of Unit Fighting Infectious Diseases & Advancing Public Health, European Commission
- Melissa Stundick, Chief, Anti-Infectives Programme, BARDA
- Ursula Theuretzbacher, Founder, Centre for Anti-Infective Agents
- Prabhavathi Fernandes, President & CEO, Cempra Pharmaceuticals
- Ankit Mahadevia, MD, President & CEO, Spero Therapeutics
- Eszter Nagy, Co-founder, President & CSO, Arsanis
- Jean de Gunzburg, Chief Scientific Officer, Da Volterra
- David Cook, Chief Scientific Officer, Blueberry Therapeutics
- Conrad Lichtenstein, Chief Scientific Officer, Nemesis Bioscience
- Steven Boakes, Associate Director of Microbiology, Cantab Anti-Infectives
Reasons to Attend:
鈥� Learn new funding opportunities from BARDA to combat antimicrobial resistance
鈥� Understand EU Commission approaches in R&D to support business growth
鈥� Reinvigorate business models with Project DRIVE-AB and to strengthen drug development
鈥� Receive new insights on microbiome profiling
Visit the website for details and earlybird rates.
